<?xml version="1.0" encoding="UTF-8"?>
<p>Exclusion of children could be justified as the incidence of COVID-19 is very low among children. However, in a condition such as Ebola, which has high mortality in children under 5 years, excluding children would compromise trial acceptance.[
 <xref rid="ref4" ref-type="bibr">4</xref>
 <xref rid="ref7" ref-type="bibr">7</xref>] As dose-finding or tolerability data in children were not available for favipiravir, the children were given weight-based doses based on the adult dosage in clinical trial of favipiravir in Ebola, for which safety data were available. Although pregnant women suffering from Ebola had a higher case-fatality rate compared to nonpregnant women, the pregnant women were excluded from this trial due to the potential risk of embryonic teratogenicity and lack of insurance.[
 <xref rid="ref7" ref-type="bibr">7</xref>]
</p>
